Axsome Therapeutics Inc. logo

Axsome Therapeutics Inc. (19X)

Market Closed
14 Jul, 20:00
XMUN XMUN
95. 18
+1.91
+2.05%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-4.27 Eps
93.27
Previous Close
Day Range
92.2 95.18
Year Range
72.12 133.55
Want to track 19X and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 20 days

Summary

19X closed today higher at €95.18, an increase of 2.05% from yesterday's close, completing a monthly increase of 4.16% or €3.8. Over the past 12 months, 19X stock gained 17.22%.
19X is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2025, missed the consensus estimates by -0.01%. On average, the company has fell short of earnings expectations by -0.16%, based on the last three reports. The next scheduled earnings report is due on Aug 04, 2025.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

19X Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?

Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 month ago
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.

Zacks | 2 months ago
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Mark Jacobson - COO Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Andrew Tsai - Jefferies Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler David Hoang - Deutsche Bank Joon Lee - Truist Securities Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Graig Suvannavejh - Mizuho Securities Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Troy Langford - TD Cowen Ami Fadia - Needham & Company Operator Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 Conference Call and Webcast.

Seekingalpha | 2 months ago

Axsome Therapeutics Inc. Dividends

19X is not paying dividends to its shareholders.

Axsome Therapeutics Inc. Earnings

11 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
4 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
5 May 2025 Date
-
Cons. EPS
-
EPS
18 Feb 2025 Date
-
Cons. EPS
-
EPS
12 Nov 2024 Date
-
Cons. EPS
-
EPS
19X is not paying dividends to its shareholders.
11 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
4 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
5 May 2025 Date
-
Cons. EPS
-
EPS
18 Feb 2025 Date
-
Cons. EPS
-
EPS
12 Nov 2024 Date
-
Cons. EPS
-
EPS

Axsome Therapeutics Inc. (19X) FAQ

What is the stock price today?

The current price is €95.18.

On which exchange is it traded?

Axsome Therapeutics Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is 19X.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Aug 04, 2025.

Has Axsome Therapeutics Inc. ever had a stock split?

No, there has never been a stock split.

Axsome Therapeutics Inc. Profile

Biotechnology Industry
Healthcare Sector
Herriot Tabuteau CEO
XMUN Exchange
US05464T1043 ISIN
US Country
712 Employees
- Last Dividend
- Last Split
19 Nov 2015 IPO Date

Overview

Axsome Therapeutics, Inc. is a forward-thinking biopharmaceutical entity dedicated to the innovation of novel treatments geared towards addressing the complexities of central nervous system (CNS) disorders. Rooted in the quest to improve patient care within the United States, Axsome stands out for its dynamic approach towards tackling conditions such as major depressive disorder, narcolepsy, obstructive sleep apnea, Alzheimer's disease agitation, and more. The foundation of the company's operations, established in 2012 and headquartered in New York, New York, underscores a commitment to pushing the boundaries of medical science, particularly in the CNS domain. Through its research collaboration with Duke University focused on smoking cessation, Axsome exemplifies its dedication to pioneering efforts in enhancing therapeutic outcomes.

Products and Services

  • Auvelity (dextromethorphan-bupropion): An innovative N-methyl-D-aspartate receptor antagonist showcasing multimodal activity, specifically indicated for the treatment of major depressive disorder, highlighting Axsome's focus on addressing mental health challenges with novel approaches.
  • Sunosi (solriamfetol): A targeted medication addressing excessive daytime sleepiness in patients battling narcolepsy or obstructive sleep apnea, underlining the company's dedication to improving quality of life for individuals with sleep disorders.

Under Development:

  • AXS-05: Currently in Phase III clinical trial for Alzheimer's disease agitation, showcasing Axsome's deep dive into neurodegenerative disease management. Additionally, it demonstrates versatility with its completion of Phase II clinical trial for smoking cessation.
  • AXS-07: An investigational medicine that has successfully completed Phase III trials, crafted for the acute treatment of migraine, providing a glimpse into Axsome's commitment to tackling severe headache disorders.
  • AXS-12: In Phase III trial to treat narcolepsy, positioning Axsome at the forefront of addressing sleep disorders with cutting-edge solutions.
  • AXS-14: Having completed Phase III trial for the treatment of fibromyalgia, this selective and potent norepinephrine reuptake inhibitor represents Axsome's venture into pain management and other potential conditions.
  • Solriamfetol: Beyond its approved use, it is under investigation in a Phase 2 trial for addressing attention-deficit/hyperactivity disorder. Additionally, its exploration extends to major depressive, binge eating, and shift work disorders, showing Axsome's holistic approach to CNS conditions.

Contact Information

Address: 22 Cortlandt Street
Phone: 212 332 3241